(±)-Felodipine-d5 |
| Catalog No.GC46289 |
An internal standard for the quantification of (±)-felodipine
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1242281-38-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
(±)-Felodipine-d5 is intended for use as an internal standard for the quantification of (±)-felodipine by GC- or LC-MS. (±)-Felodipine is an inhibitor of L-type calcium channels.1 It induces relaxation of precontracted isolated porcine coronary artery segments (EC50 = 0.15 nM), which highly express L-type calcium channels.2 (±)-Felodipine is selective for L-type calcium channels over N-, R-, and P/Q-type channels at 10 µM, as well as the T-type Cav3.2 channel (IC50 = 6.8 µM).1,3 (±)-Felodipine preferentially inhibits L-type calcium channels in isolated rat portal vein over rat left ventricle (IC50s = 33.9 and 3,981 nM, respectively).4 It decreases mean arterial blood pressure and total peripheral resistance in a rabbit model of hypertension induced by renal artery ligation when administered intravenously at doses of 30 and 100 nmol/kg.5
1.Furukawa, T., Yamakawa, T., Midera, T., et al.Selectivities of dihydropyridine derivatives in blocking Ca2+ channel subtypes expressed in Xenopus oocytesJ. Pharmacol. Exp. Ther.291(2)464-473(1999) 2.Johnson, J.D., and Fugman, D.A.Calcium and calmodulin antagonists binding to calmodulin and relaxation of coronary segmentsJ. Pharmacol. Exp. Ther.226(2)330-334(1983) 3.Perez-Reyes, E., Van Deusen, A.L., and Vitko, I.Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: Block by antihypertensives, antiarrhythmics, and their analogsJ. Pharmacol. Exp. Ther.328(2)621-627(2009) 4.Ljung, B.Vascular selectivity of felodipine: Experimental pharmacologyJ. Cardiovasc. Pharmacol.15(Suppl 4)S11-S16(1990) 5.Bolt, G.R., and Saxena, P.R.Acute systemic and regional hemodynamic effects of felodipine, a new calcium antagonist, in conscious renal hypertensive rabbitsJ. Cardiovasc. Pharmacol.6(4)707-712(1984)
| Cas No. | 1242281-38-4 | SDF | |
| Canonical SMILES | CC1=C(C(C(C(OC([2H])([2H])C([2H])([2H])[2H])=O)=C(N1)C)C2=C(C(Cl)=CC=C2)Cl)C(OC)=O | ||
| Formula | C18H14Cl2D5NO4 | M.Wt | 389.3 |
| Solubility | Chloroform: soluble | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5687 mL | 12.8436 mL | 25.6871 mL |
| 5 mM | 0.5137 mL | 2.5687 mL | 5.1374 mL |
| 10 mM | 0.2569 mL | 1.2844 mL | 2.5687 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 4 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *